ARTICLE | Product Development

Nov. 23 Quick Takes: Aadi’s Fyarro approved for rare sarcoma

Plus BMS’s Zeposia, LoQus23’s seed round, Simcere’s COVID antiviral and more

November 24, 2021 1:01 AM UTC

Aadi Bioscience Inc. (NASDAQ:AADI) is aiming to launch Fyarro nab-sirolimus drug next quarter after FDA approved therapy to treat malignant perivascular epithelioid cell tumor, a rare sarcoma with no other approved treatment options. The albumin-bound formulation of mTOR inhibitor sirolimus led to a 39% objective response rate in a Phase II trial, including two complete responses among 31 evaluable subjects.

Six months after FDA approved Zeposia ozanimod from Bristol Myers Squibb Co. (NYSE:BMY) to treat ulcerative colitis, the European Commission has followed suit by authorizing the drug’s sale for the same indication. The S1PR1 modulator is also approved in both geographies to treat multiple sclerosis. Acquired via BMS’s takeout of Celgene Corp., which had itself acquired Receptos Inc. for $7.2 billion in 2015 to gain Zeposia’s rights, the therapy accounted for $86 million in sales to BMS across the first nine months of 2021...